Innovative Trials to help advance blood cancer care and research with inaugural US charity partnership
Innovative Trials, a global clinical trials patient recruitment company with bases in both the UK and US, has selected the Multiple Myeloma Research Foundation (MMRF) as its first-ever US-based charity partner. Through the strategic charity partnership, which will last until May 2024, Innovative Trials is committing to help improve blood cancer care and advance research into multiple myeloma, with the ultimate aim of finding cures for all patients.
Kate Shaw, Founder and CEO of Innovative Trials, said: “Giving back in the form of supporting charity work has always been important to us as a company. With the opening of our US office last year and the subsequent growth of our team in North America, we wanted to ensure our philanthropy would make a difference to people in the US as well as the UK, where we have our HQ. “With a focus on finding new treatments and a cure for multiple myeloma, the Multiple Myeloma Research Foundation seemed like a perfect fit for us. We hope we can contribute even further to accelerate new discoveries through our fundraising, and hopefully get closer to the holy grail of a cure.”
Innovative Trials works with some of the world’s biggest pharmaceutical companies to accelerate the development of life-changing treatments, particularly in the field of oncology. It has been involved with hundreds of clinical trials and played a part in more than six new treatments being approved for patients across the world.
Innovative Trials is committed to supporting charitable causes and is aiming to raise $4,000 for the MMRF over the next year. The charity is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. It drives the development and delivery of next-generation therapies, leverages data to identify optimal and more personalized treatment approaches, and empowers myeloma patients and the broader community with information and resources to extend their lives.
Alongside its fundraising for the MMRF, Innovative Trials will also raise vital funds for the Great Ormond Street Hospital (GOSH) Children’s Charity in the UK. The company’s fundraising committee is planning a series of activities to raise money – its summer BBQ has already raised £900 for the GOSH Children’s Charity. It will also raise funds at external US conferences and events. The senior leadership team has promised to match the amount of money raised, up to $2,000, for the MMRF.
The company has previously raised thousands of pounds for Crohn’s and Colitis UK, Alzheimer’s Research UK and MS Society in the UK.
-Ends-
For more information, please contact Laura Gibson at Presence Media on +44 7771 933609 or [email protected]
Notes to editors
About Innovative Trials
Founded in 2010, Innovative Trials works alongside pharmaceutical and clinical research organisations to ensure that patients enrol into clinical trials in a timely manner and are fully informed of what the research will involve for themselves and their families. This enables potential new treatments to come to market as early as possible to provide alternative therapeutic options for present and future patients.
Based in Letchworth Garden City in Hertfordshire, Innovative Trials employs over 60 members of staff in the UK. The company works internationally with a further 65 people stationed overseas in 70 countries to help clinical trial researchers recruit eligible patients and keep them involved.
For more information, visit www.innovativetrials.com
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $500 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit the MMRF website.